Notice of Refund | Feb 1, 2018 | PAPER | BOARD |
Petitioner's Refund Request | Jan 24, 2018 | PAPER | PETITIONER |
Decision - Denying Institution of Inter Partes Review | Dec 11, 2017 | PAPER | BOARD |
Amendment to the Claims, Patent Appl. No. 12/285,887 | Dec 11, 2017 | EXHIBIT | BOARD |
Illum Declaration | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson Declaration | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Sawchuk Declaration | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Di Leo 2010 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Ohno 2010 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Greenlee 2000 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson 1996 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Hortobagyi Cancer Investigation 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Johnston 1997 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Pritchard 1997 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Howell 1992 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Jordan 1995 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Morrow 1993 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Wiebe 1993 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Jordan Supp. 1992 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Jordan 1992 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Minton 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Preliminary Response to Petition for Inter Partes Review of U.S. Patent No. 8,329,680 | Nov 17, 2017 | PAPER | PATENT OWNER |
Di Leo 2014 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Pritchard 2010 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Fornier 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Jordan Supp. 1995 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Buzdar Clin. Oncol. 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Osborne 2002 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Fallowfield 2006 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson SABCS 2014 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Vergote 2003 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Agrawal 2009 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Gupta Ch. 2 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Grese 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Hortobagyi New Eng. J. Med. 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Masamura 1994 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Kelloff 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Dukes 1994 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Howell 2002 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson 2001 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson Clin. Ther. 2003 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Labrie 2004 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Van de Velde 1996 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Labrie 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Hortobagyi 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Hortobagyi 1997 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Dowsett 1995 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Hayes 1995 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Howell 1997 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Haarstad 1992 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
AACR Journals Online | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
McLeskey Declaration | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Innovative Research | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
PDR 1999 Nolvadex | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
PDR 1999 Femara | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Rauschning 1994 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Thomas 1993 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
July 14 Trial Tr. | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Bratherton 1984 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Cohen 1995 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Sweetana 1996 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Beyea 1996 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson 2009 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson 2012 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Ellis 2015 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson 2004 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Bellmunt 1991 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Chia 2008 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Johnston 2013 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson 2005 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Johnston 2004 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Pharma Marketletter 2004 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Cancer Weekly April 2004 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Baumann 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Pyrhonen 1994 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Stenbygaard 1993 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson 2014 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Barrios 2012 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson Eur. J. Cancer 2005 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Clinical Practice Guidelines 2003 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Vergote 2006 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Kuter 2012 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Buzdar 2006 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Remington's Ch. 91 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Aulton Ch. 1 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Remington's Ch. 75 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Buzdar 2002 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Vidal 1997 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Forrest Mylan Declaration | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Ansel Ch. 12 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Ansel Ch. 13 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Ansel Ch. 10 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Greenblatt 1978 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Lavy 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
PDR 1999 Estrace | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Eagle 1949 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Remington's Ch. 9 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Bonneterre 1985 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Muss 1990 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Remington's Ch. 84 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Buzdar 1994 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Groves Ch. 2 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Gupta Ch. 1 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Baselga 2003 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Vidal 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
ABPI 1999-2000 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Remington's Ch. 89 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Aulton Ch. 13 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Ansel Ch. 7 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Aulton Ch. 18 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Aulton Ch. 19 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Gao 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Merck Index 1996 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Avis Ch. 4 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Aulton Ch. 6 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Porras 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Ansel Ch. 14 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Avis Ch. 2 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Buzdar ASCO 2001 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Wade 1993 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Lundeen 1997 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Buzdar 2003 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Strickley I 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Avis Ch. 3 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Zuidema 1994 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Ballard 1968 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Hirano 1981 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Litchfield 1961 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Buzdar 1996 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Lifschitz 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Chu 1960 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Gupta Ch. 17 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Huber 1965 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Affidavit of Internet Archive | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
PDR 1999 Arimidex | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Skougaard 1966 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Levine 1966 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Yarinsky 1970 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Sawchuk Mylan Declaration | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Lachman's 1986 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Illum Mylan Declaration | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson Mylan Declaration | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Buzdar 1997 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Jonat 1996 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Dombernowsky 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Buzdar 2001 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Dowsett Clin. Cancer Res. 1995 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Goss 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Hoffken 1992 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Hortobagyi 1985 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Rose 1985 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Koyama 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Abrams 1990 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Jonat 2013 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Goss 1986 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Stenger 2017 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Wright Ch. 4 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Huynh 1993 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Applied Biopharmaceutics 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Abrams 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Dowsett 1989 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Robertson 2016 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Cristofanilli 2016 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Strickley II 2000 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Martel 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Chatterjee 1993 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Sibonga 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
PDR 1999 Inderal LA | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
InnoPharma Decision | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
PTAB Order | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Dipippo 1997 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Al-Matubsi 1998 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Oleksowicz Mylan Declaration | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Burgess Amneal Declaration | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
D'Agostino 1990 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Rowland Ch. 13 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Shapiro 1965 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
FDA Guidance 1999 | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
InnoPharma Petition | Nov 17, 2017 | EXHIBIT | PATENT OWNER |
Ex. 3001 | Nov 2, 2017 | EXHIBIT | BOARD |
Order Denying Petitioner's Requests for Authorization to File a Motion to Withdraw the Petition And Motion for Joinder | Nov 2, 2017 | PAPER | BOARD |
Patent Owner's Power of Attorney Pursuant to 37 C.F.R. 42.10(b) | Aug 25, 2017 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notices Pursuant to 37 C.F.R. 42.8 | Aug 25, 2017 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | Aug 17, 2017 | PAPER | BOARD |
Howell et al., Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer, 74 BRIT. J. CANCER 300-08 (1996) | Aug 4, 2017 | EXHIBIT | PETITIONER |
AstraZeneca's Preliminary Response in Mylan Pharms. Inc. v. AstraZeneca AB, Paper No. 10, IPR2016-01325 (P.T.A.B. Oct. 6, 2016) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Wakeling et al., A Potent Specific Pure Antiestrogen with Clinical Potential, 51 CANCER RESEARCH 3867-3873 (1991) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Smith, Analysis of Oil-Based Pharmaceuticals, 49 J. AMERICAN OIL CHEMISTS SOCIETY 409-13 (1972) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Jorgensen, Pharmacokinetic Studies in Volunteers of Intravenous and Oral Cis (Z)-Flupentixol and Intramuscular Cis (Z)-Flupentixol Decanoate in Viscoleo, 18 EUR. J. CLIN. PHARMACOL. 355-60 (1980) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Fabian, Clinical Pharmacology of Tamoxifen in Patients with Breast Cancer: Correlation with Clinical Data, 48 CANCER 876-82 (1981) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Copy of Prosecution History for the U.S. Patent No. 8,466,139 | Aug 4, 2017 | EXHIBIT | PETITIONER |
PETITION FOR INTER PARTES REVIEW OF U.S. PATENT NO. 8,329,680 UNDER 35 U.S.C. 311-319 AND 37 C.F.R. 42.100 ET SEQ | Aug 4, 2017 | PAPER | PETITIONER |
PETITIONER FRESENIUS KABI'S POWER OF ATTORNEY
U.S. PATENT NO. 8,329,680 | Aug 4, 2017 | PAPER | PETITIONER |
U.S. Patent No. 8,329,680 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Exhibit Reserved | Aug 4, 2017 | EXHIBIT | PETITIONER |
Exhibit Reserved | Aug 4, 2017 | EXHIBIT | PETITIONER |
Exhibit Reserved | Aug 4, 2017 | EXHIBIT | PETITIONER |
Exhibit Reserved | Aug 4, 2017 | EXHIBIT | PETITIONER |
Copy of Prosecution History for U.S. Patent No. 6,774,122 | Aug 4, 2017 | EXHIBIT | PETITIONER |
McLeskey et al., Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors, 4 CLIN. CANCER RESEARCH 697-711 (1998) | Aug 4, 2017 | EXHIBIT | PETITIONER |
O'Regan et al., Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth, 90 J. NAT'L CANCER INST. 1552-1558 (1998) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Order, AstraZeneca Pharms. LP v. Sandoz Inc., No. 14-03547 (D.N.J. July 29, 2015), ECF No. 102 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Institution Decision in Mylan Pharms. Inc. v. AstraZeneca AB, Paper No. 11, IPR2016-01325 (P.T.A.B. Dec. 14, 2016) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Declaration of Diane Burgess, Ph.D. and Accompanying Exhibits | Aug 4, 2017 | EXHIBIT | PETITIONER |
Declaration of Richard Bergstrom, Ph.D. and Accompanying Exhibits | Aug 4, 2017 | EXHIBIT | PETITIONER |
Declaration of Dorraya El-Ashry, Ph.D. and Accompanying Exhibits | Aug 4, 2017 | EXHIBIT | PETITIONER |
Declaration of Adrian Harris, Ph.D. and Accompanying Exhibits | Aug 4, 2017 | EXHIBIT | PETITIONER |
U.S. Patent No. 4,659,516 | Aug 4, 2017 | EXHIBIT | PETITIONER |
DeLuca, Formulation of Small Volume Parenterals, PHARMACEUTICAL DOSAGE FORMS: PARENTERAL MEDICATIONS VOLUME 1 (Avis ed., 2d ed. 1992) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Declaration Under 37 C.F.R. 1.132 of Ronald J. Sawchuk in Application No. 12/285,887 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Declaration Under 37 C.F.R. 1.132 of Paul Richard Gellert in Application No. 10/872,784 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Faslodex Label | Aug 4, 2017 | EXHIBIT | PETITIONER |
DiPiro, Concepts in Clinical Pharmacokinetics (2010) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Qiu, Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice (2009) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Tozer, Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy (2006) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Caldwell, An Introduction to Drug Disposition: The Basic Principles of Absorption, Distribution, Metabolism, and Excretion, 23 Toxicologic Pathology 102 (1995) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Wills, "Basic Pharmacodynamic Concepts and Models," Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology (1994) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Derendorf, Handbook of Pharmacokinetic/Pharmacodynamic Correlation 53 (1995) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Mager, Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans, DRUG METAB. PHARMACOKINET. (2009) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Colburn, Simultaneous Pharmacokinetic/Pharmacodynamic Modeling, PHARMACODYNAMICS AND DRUG DEVELOPMENT: PERSPECTIVES IN CLINICAL PHARMACOLOGY (1994) | Aug 4, 2017 | EXHIBIT | PETITIONER |
White, Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization, 57 ANTIMICROBIAL AGENTS & CHEMOTHERAPY 5802 (2013) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Nicholson, R.I. et al., Responses To Pure Antiestrogens (ICI 164384, ICI 82780) In Estrogen-Sensitive And -Resistant Experimental And Clinical Breast Cancer, ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, Vol. 61:148-163 (1995) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Riffkin, Castor Oil as a Vehicle for Parenteral Administration of Steroid Hormones, 53 J. PHARM. SCI. 891-895 (1964) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Finley, New Drug Being Tested in Breast Cancer Study, SAN ANTONIO EXPRESS-NEWS, Sept. 20, 1997 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Uges, Plasma or Serum in Therapeutic Drug Monitoring and Clinical Toxicology, 10 PHARMACEUTISCH WEEKBLAD SCIENTIFIC EDITION 185-88 (1988) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Dukes et al., Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys, 135 J. ENDOCRINOLOGY 239-247 (1992) | Aug 4, 2017 | EXHIBIT | PETITIONER |
WO 03/006064 | Aug 4, 2017 | EXHIBIT | PETITIONER |
DeFriend et al., Investigation of a New Pure Antiestrogen (ICI 182780) in Women with Primary Breast Cancer, 54 CANCER RESEARCH 408-414 (1994) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Osborne et al., Comparison of the Effects of a Pure Steroidal Antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer, 87 J. NAT'L CANCER INST. 746-750 (1995) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Alan E. Wakeling & Jean Bowler, ICI 182,780: A New Antioestrogen with Clinical Potential, 43 J. STEROID BIOCHEM. MOLEC. BIOL. 173-177 (1992) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Howell, A. et al., Clinical Studies With The Specific 'Pure' Antiestrogen ICI 182780, THE BREAST, Vol. 5:192-195 (1996) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Copy of Prosecution History for U.S. Patent No. 8,329,680 (downloaded from PAIR) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Robertson, J.F.R. et al., Duration Of Remission To ICI 182,780 Compared To Megestrol Acetate In Tamoxifen Resistant Breast Cancer, THE BREAST, Vol. 6:186-189 (1997) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Robertson, Fulvestrant Versus Anastrozole for the Treatment of Advanced Breast Carcinoma in Postmenopausal Women: A Prospective Combined Analysis of Two Multicenter Trials, 98 CANCER 229-38 (2003) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Howell, Response to a Specific Antioestrogen (ICI 182780) in Tamoxifen-Resistant Breast Cancer, 345 LANCET 989-90 (1995) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Copy of Prosecution History for the U.S. Patent No. 7,456,160 | Aug 4, 2017 | EXHIBIT | PETITIONER |
U.S. Patent No. 5,183,814 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Parczyk, K. et al., Progesterone Receptor Repression by Estrogens in Rat Uterine Epithelial Cells, 63 J. STEROID BIOCHEMISTRY & MOLECULAR BIOLOGY 309 (1997) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Anderson, Models of New Antioestrogen Action in Vivo: Primary Tumours, 5 THE BREAST 186-91 (1996) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Buzdar, Update on Endocrine Therapy for Breast Cancer, 4 CLINICAL CANCER RESEARCH 527-34 (1998) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Howell, New Endocrine Therapies for Breast Cancer, 32A EUR. J. CANCER 576-88 (1996) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Howell, The Definition of the 'No Change' Category in Patients Treated with Endocrine Therapy and Chemotherapy for Advanced Carcinoma of the Breast, 24 EUR. J. CANCER CLIN. ONCOL. 1567-72 (1988) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Nicholson, "Pure Antioestrogens in Breast Cancer: Experimental and Clinical Observations," Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects, Proceedings of an International Symposium, Milano 347-60 (1994) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Santen, Use of Aromatase Inhibitors in Breast Carcinoma, 6 ENDOCRINE-RELATED CANCER 75-92 (1999) | Aug 4, 2017 | EXHIBIT | PETITIONER |
EP 0 346 014 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Howell, Response to a Specific Antioestrogen (ICI 182780) in Tamoxifen-Resistant Breast Cancer, 345 LANCET 29-30 (1995) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Dukes, Antiuterotrophic Effects of the Pure Antioestrogen ICI 182,780 in Adult Female Monkeys (Macaca nemestrina): Quantitative Magnetic Resonance Imaging, 138 J. ENDOCRINOLOGY 203-09 (1993) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Wakeling, The Future of New Pure Antioestrogens in Clinical Breast Cancer, 25 BREAST CANCER RESEARCH & TREATMENT 1-9 (1993) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Selective Estrogen Receptor Modulators (SERMs), BREASTCANCER.ORG (last modified Nov. 5, 2015) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Howell, Fulvestrant Revisited: Efficacy and Safety of the 500-mg Dose, 11 CLINICAL BREAST CANCER 204-10 (2011) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Thomas, The Effects of ICI 182,780, a Pure Anti-Oestrogen, on the Hypothalamic-Pituitary-Gonadal Axis and on Endometrial Proliferation in Pre-Menopausal Women, 9 HUMAN REPRODUCTION 1991-96 (1994) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Freireich, Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man, 50 CANCER CHEMOTHERAPY REPORTS 219-44 (1966) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Equivalent Surface Area Dosage Conversion Factors (2007) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Clarke, Antiestrogen Resistance in Breast Cancer and the Role of Estrogen Receptor Signaling, 22 ONCOGENE 7316-39 (2003) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Gusterson, Do we now have a relevant animal model for breast cancer? 1 BREAST CANCER RESEARCH 2-4 (1999) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Johnston, Changes in Estrogen Receptor, Progesterone Receptor, and pS2 Expression in Tamoxifen-Resistant Human Breast Cancer, 55 CANCER RESEARCH 3331-38 (1995) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Waynforth, LASA Good Practice Guidelines: Administration of Substances (Rat, Mouse, Guinea Pig, Rabbit) (Oct. 1998) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Mackey, Tolerability of Intramuscular Injections of Testosterone Ester in Oil Vehicle, 10 HUMAN REPRODUCTION 862-65 (1995) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Kern, "Role of Angiogenesis in the Transition to Hormone Independence and Acquisition of the Metastatic Phenotype," Endocrinology of Breast Cancer 169-86 (Manni ed., 1999) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Neubauer, Changes in Tumour Biological Markers during Primary Systemic Chemotherapy (PST), 28 ANTICANCER RESEARCH 1797-804 (2008) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Spiegel & Noseworthy, Use of Nonaqueous Solvents in Parenteral Products, 52 J. PHARM. SCIS. 917-27 (1963) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Taucher, Sequential Steroid Hormone Receptor Measurements in Primary Breast Cancer with or without Intervening Primary Chemotherapy, 10 ENDOCRINE-RELATED CANCER 91-98 (2003) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Turner, Administration of Substances to Laboratory Animals: Routes of Administration and Factors to Consider, 50 J. AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE 600-13 (2011) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Robertson, J.F.R. et al., (1999) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Kohler 1992 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Petition for Inter Partes Review in Mylan Pharms. Inc. v. AstraZeneca AB, Paper No. 2, IPR2016-01325 (P.T.A.B. June 29, 2016) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Handbook of Pharmaceutical Excipients (Wade ed., 2d. ed. 1994) | Aug 4, 2017 | EXHIBIT | PETITIONER |
FDA's Inactive Ingredient Database (1996) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Drugs@FDA Glossary of Terms, U.S. FOOD & DRUG ADMINISTRATION (last updated Feb. 2, 2012) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Adam, "Pharmacokinetics of Agents in Relation to Response," Endocrine Management of Cancer: Biological Bases 112-24 (1988) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Baselga, Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer, 14 J. CLINICAL ONCOLOGY 737-44 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Goldenberg, Trastuzumab, a Recombinant DNA-Derived Humanized Monoclonal Antibody, a Novel Agent for the Treatment of Metastatic Breast Cancer, 21 CLINICAL THERAPEUTICS 309-18 (1999) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Wilkinson, Tamoxifen (Nolvadex*) Therapy - Rationale for Loading Dose Followed by Maintenance Dose for Patients with Metastatic Breast Cancer, 10 CANCER CHEMOTHERAPY PHARMACOLOGY 33-35 (1982) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Wunsche, Estrogenic Regulation of Clusterin mRNA in Normal and Malignant Endometrial Tissue, 76 INT. J. CANCER 684-88 (1998) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Chwalisz, Modulation of Oestrogenic Effects by Progesterone Antagonists in the Rat Uterus, 4 HUMAN REPRODUCTION UPDATE 570-83 (1998) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Robertson, Fulvestrant (Faslodex) - How to Make a Good Drug Better, 12 ONCOLOGIST 774-84 (2007) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Ansel, "Dosage Form Design: Biopharmaceutic and Pharmacokinetic Considerations," Pharmaceutical Dosage Forms and Drug Delivery Systems 101-41 (7th ed. 1999) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Lee, Standard Deviation and Standard Error of the Mean, 68 KOREAN J. ANESTHESIOLOGY 220-23 (2015) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Altman, Standard Deviations and Standard Errors, 331 BMJ 903 (2005) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Tse, Bioavailability of Parenteral Drugs I. Intravenous and Intramuscular Doses, 34 J. PARENTERAL DRUG ASSOCIATION 409-21 (1980) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Licciardi, Oral Versus Intramuscular Progesterone for In Vitro Fertilization: A Prospective Randomized Study, 71 FERTILITY & STERILITY 614-18 (1999) | Aug 4, 2017 | EXHIBIT | PETITIONER |
August 21, 2008 Applicant Amendment and Response in Application No. 10/872,784 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Balant-Gorgia, Pharmacokinetic Optimisation of the Treatment of Psychosis, 25 CLIN. PHARMACOKINET. 217-36 (1993) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Chien, Solubilization of Steroids by Multiple Co-Solvent Systems, 23 CHEM. PHARM. BULL. 1085-90 (1975) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Ford, "Parenteral Products," Pharmaceutics: The Science of Dosage Form Design 359-80 (Aulton ed., 1988) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Cunliffe-Beamer, "Biomethodology and Surgical Techniques," The Mouse in Biomedical Research, Volume III: Normative Biology, Immunology, and Husbandry 401-37 (Foster ed., 1983) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Way, "Cosolvent Use in Injectable Formulations," Injectable Drug Development: Techniques to Reduce Pain and Irritation 215-66 (Gupta ed., 1999) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Nema, Excipients and Their Use in Injectable Products, 51 PDA J. PHARM. SCI. & TECH. 166-71 (1997) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Ogasawara, Effects of Experimental Chemoendocrine Therapy with a Combination of a Pure Antiestrogen and 5-Fluorouracil on Human Breast Cancer Cells Implanted in Nude Mice, 29 SURGERY TODAY 149-56 (1999) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Tse, Bioavailability of Parenteral Drugs II. Parenteral Doses Other Than Intravenous and Intramuscular Routes, 34 J. PARENTERAL DRUG ASSOCIATION 484-95 (1980) | Aug 4, 2017 | EXHIBIT | PETITIONER |
U.S. Patent No. 4,212,863 | Aug 4, 2017 | EXHIBIT | PETITIONER |
Oldham, "Mass Transport to Electrodes," Chemical Kinetics 79-143 (Bamford ed., 1986) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Powell, Compendium of Excipients for Parenteral Formulations, 52 PDA J. PHARM. SCI. & TECH. 238-311 (1998) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Remington's Pharmaceutical Sciences 1538-39, 1545-50, 1686-88 (18th ed. 1990) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Roberts, Investigation of Cosolvent Effects on the Solvation of AOT Reverse Micelles in Supercritical Ethane, 102 J. PHYS. CHEM. B 9074-80 (1998) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Sawka, Physiological Consequences of Hypohydration: Exercise Performance and Thermoregulation, 24 MEDICINE & SCIENCE IN SPORTS & EXERCISE 657-70 (1992) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Simmons, The Laboratory Mouse: Selection and Management 127-28 (1970) | Aug 4, 2017 | EXHIBIT | PETITIONER |
Ting, Solubility of Naproxen in Supercritical Carbon Dioxide with and without Cosolvents, 32 IND. ENG. CHEM. RES. 1471-81 (1993) | Aug 4, 2017 | EXHIBIT | PETITIONER |
USP 23 - NF 18, The United States Pharmacopeia - The National Formulary 13-14 (1995) | Aug 4, 2017 | EXHIBIT | PETITIONER |
MOTION FOR JOINDER UNDER 35 U.S.C. 315(c) AND 37 C.F.R. 42.22 AND 42.122(b) | Aug 4, 2017 | PAPER | PETITIONER |